GlassScriptPhysician profile
Charles P Biediger
NPI 1033127022
$6,524.14
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $6,023 · 2021: $54.99 · 2022: $185.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,774.60 | 2020 | |
| Optinose US, INC. | $167.03 | 2019-2022 | |
| Inspire Medical Systems, INC. | $146.38 | 2020 | |
| Arrinex, INC. | $117.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $87.66 | 2020-2022 | |
| Acclarent, INC | $56.25 | 2019-2022 | |
| Genzyme Corporation | $47.08 | 2019 | |
| Checkpoint Surgical, INC | $29.06 | 2020 | |
| Aerin Medical INC. | $25.52 | 2022 | |
| Alk-Abello, INC | $24.95 | 2020 | |
| Stryker Corporation | $17.78 | 2019 | |
| Davol INC. | $17.52 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Biediger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.